Related references
Note: Only part of the references are listed.
Article
Infectious Diseases
Dieter Munker et al.
Summary: Objective evaluation of pulmonary function impairment after COVID-19 in persistently symptomatic and asymptomatic patients revealed significant PFI in patients of all disease severities, with mechanical ventilation being a major risk factor. Risk factors for DLCO impairment included COPD, SARS-CoV-2 antibody titer, and CT score in hospitalized patients. Gas exchange abnormalities were found during cycle exercise in some patients with mild disease courses.
Article
Medicine, General & Internal
Robert L. Gottlieb et al.
Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Review
Pediatrics
Kavita Dave et al.
Summary: CFTR modulators are oral drugs that improve the function of the CFTR protein to treat cystic fibrosis, with ivacaftor as a highly effective potentiator that is available clinically worldwide. However, for common CFTR mutations like F508del, combination therapy of correctors and potentiators is required for clinical efficacy.
PEDIATRIC PULMONOLOGY
(2021)
Article
Respiratory System
Fabio Anastasio et al.
Summary: This study evaluated the mid-term clinical impact of COVID-19 on respiratory function in 379 patients, finding that lung damage during acute infection correlates with the reduction in pulmonary function.
EUROPEAN RESPIRATORY JOURNAL
(2021)
Article
Medicine, General & Internal
Christopher C. Butler et al.
Summary: The use of azithromycin does not show significant benefits in reducing recovery time or risk of hospitalization for people with suspected COVID-19 in the community. This finding underscores the importance of prudent antibiotic use during the pandemic, as increased antibiotic use can lead to antimicrobial resistance.
Article
Cardiac & Cardiovascular Systems
Yousaf B. Hadi et al.
Summary: This study reveals that patients with cystic fibrosis are at higher medical risk and face poorer outcomes when infected with COVID-19, particularly in terms of hospitalization rate, critical care need, and acute renal injury.
RESPIRATORY MEDICINE
(2021)
Article
Respiratory System
Lutz Naehrlich et al.
Summary: The study investigated the impact of SARS-CoV-2 infection on CF patients, finding a higher incidence among lung transplant recipients. CF patients showed higher rates of hospital admission and intensive care compared to the general population across all age groups, but the case fatality rate was not significantly different.
JOURNAL OF CYSTIC FIBROSIS
(2021)
Article
Multidisciplinary Sciences
Carla Colombo et al.
Summary: In patients with cystic fibrosis, SARS-CoV-2 infection resulted in relatively mild symptoms and outcomes, with no significant differences observed between those who tested positive and negative for the virus. Fever, cough, asthenia, and dyspnea were the most commonly reported symptoms, and 50% of cases required hospitalization but none needed ICU admission.
Review
Respiratory System
Pedro Mondejar-Lopez et al.
Summary: The early stages of lung involvement in cystic fibrosis can be asymptomatic, making early detection challenging. Currently, methods such as LCI, CT, and MRI are used to monitor the progression of lung disease and evaluate responses to interventions. Collaboration between pulmonology and radiology is crucial for improving care and outcomes in young CF patients.
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2021)
Article
Respiratory System
Guillaume Beltramo et al.
Summary: Influenza epidemics were initially considered as a suitable model for the COVID-19 epidemic, but data shows that patients with chronic respiratory diseases are at higher risk for severe forms of COVID-19 and have a higher mortality rate compared to influenza patients.
EUROPEAN RESPIRATORY JOURNAL
(2021)
Article
Infectious Diseases
Alberto Fortini et al.
Summary: Few data are currently available on persistent symptoms and late organ damage in patients who have suffered from COVID-19. A prospective study aimed to evaluate the results of a follow-up program for patients discharged from a nonintensive COVID-19 ward. 77.8% of COVID-19 patients continue to complain of symptoms 3-6 months after hospital discharge, with exertional dyspnea significantly associated with lung US abnormalities and diffusing capacity alterations.
Article
Geriatrics & Gerontology
Matteo Tosato et al.
Summary: Older adults who have been hospitalized for COVID-19 frequently experience persistent symptoms, with fatigue, dyspnea, joint pain, and cough being the most common. The likelihood of symptom persistence is higher in those who have experienced more symptoms during acute COVID-19.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2021)
Article
Immunology
Nitipong Permpalung et al.
Summary: The impact of COVID-19 on lung transplant recipients remains unknown. This study found that LTRs with COVID-19 were more likely to develop decline in lung allograft function, secondary infections, and require rehospitalization compared to controls. There were no acute rejection episodes observed within 90 days post infection. Further research is needed to determine if LTRs who do not recover baseline lung function within 90 days may progress to chronic lung allograft dysfunction.
Review
Respiratory System
Hannah R. Mathew et al.
Summary: Individuals with cystic fibrosis (CF) do not appear to have a higher risk of contracting SARS-CoV-2 infection compared to the general population, although subsets within the CF population, such as organ transplant recipients, may experience a more severe clinical course of COVID-19. Protective mechanisms in the CF population may include pre-pandemic social isolation practices, infection prevention and control knowledge, altered expression of angiotensin-converting enzyme, and the use of certain medications. Ongoing monitoring of the risk of COVID-19 in individuals with CF is necessary as the pandemic continues.
BMC PULMONARY MEDICINE
(2021)
Review
Respiratory System
R. Torres-Castro et al.
Summary: Research found that lung function of patients post-COVID-19 infection may be impaired, with diffusion capacity being the most affected, and respiratory function tests including DLCO, restrictive pattern, and obstructive pattern.
Review
Respiratory System
Kathleen J. Ramos et al.
Summary: In the past decade, oral small molecule therapies have been developed to address the basic cystic fibrosis transmembrane conductance regulator (CFTR) protein defect, offering highly effective modulator treatment (HEMT) for a large majority of CF patients. However, some CF patients eligible for HEMT may face challenging situations due to comorbidities and exclusion from original clinical trials.
JOURNAL OF CYSTIC FIBROSIS
(2021)
Article
Immunology
Jonathan Messika et al.
Summary: The COVID-19 infection in the French cohort of lung transplant patients was severe, with most cases requiring hospitalization and a survival rate of 85.7%. Among the critically ill patients, invasive mechanical ventilation was required for over half, and thrombotic events occurred in 4 patients. Overweight was significantly associated with the risk of death.
Review
Immunology
Yorg Azzi et al.
Summary: Solid organ transplantation has been significantly impacted by the coronavirus pandemic, with high mortality rates reported in recipients. The pandemic led to complexities in transplantation, including new questions regarding donor and recipient screening, and decisions on continuing transplantation based on clinical implications of COVID-19 infection. The clinical outcomes of COVID-19 in transplantation may vary depending on the type of transplanted organ and recipient comorbidities.
Letter
Respiratory System
Justine Frija-Masson et al.
EUROPEAN RESPIRATORY JOURNAL
(2020)
Article
Medicine, Research & Experimental
Yu Zuo et al.
Letter
Infectious Diseases
Jingjing You et al.
JOURNAL OF INFECTION
(2020)
Review
Endocrinology & Metabolism
Giuseppe Pugliese et al.
ACTA DIABETOLOGICA
(2020)
Article
Respiratory System
Elliot McClenaghan et al.
JOURNAL OF CYSTIC FIBROSIS
(2020)
Article
Respiratory System
Yiying Huang et al.
RESPIRATORY RESEARCH
(2020)
Review
Respiratory System
Carlo Castellani et al.
JOURNAL OF CYSTIC FIBROSIS
(2018)
Article
Respiratory System
Oded Breuer et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2018)
Article
Respiratory System
Anne L. Stephenson et al.
EUROPEAN RESPIRATORY JOURNAL
(2015)
Article
Respiratory System
Philip H. Quanjer et al.
EUROPEAN RESPIRATORY JOURNAL
(2012)
Review
Respiratory System
Michael W. Konstan et al.
JOURNAL OF CYSTIC FIBROSIS
(2012)
Article
Endocrinology & Metabolism
E. Cacciari et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2006)
